EVALUATION OF CARDIOVASCULAR RISK AND OSTEOMETABOLIC ALTERATIONS IN A POPULATION OF PATIENTS AFFECTED BY RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS OF A MULTIDISCIPLINARY PROSPECTIVE STUDY in Annals of the Rheumatic Diseases
2023
AOU Città della Salute di Torino
Tipo pubblicazione
Conference Abstract
Autori/Collaboratori (7)Vedi tutti...
Parisi S
Azienda Ospedaliero Universitaria Città Della Salute e della Scienza di Torino, Rheumatology Unit, Turin, Italy
Ditto MC
Azienda Ospedaliero Universitaria Città Della Salute e della Scienza di Torino, Rheumatology Unit, Turin, Italy
Lopez C
Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Endocrinology, Diabetes and Metabolism Unit, Department of Medical Sciences, Turin, Italy
et alii...
Abstract
Background: Rheumatoid Arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality and osteometabolic alterations risk, associated with chronic inflammation, the use of glucocorticoids (GC) and the reduced physical exercise.[1] Objectives: The objective of the study is to cross-sectionally estimate cardiovascular risk and osteometabolic status in patients (pts) with RA and to evaluate the association with some disease parameters such as positivity of autoantibodies, disease activity and steroid therapy. Methods: At the current time, 61 consecutive pts with diagnosis of RA, admitted to the Rheumatology Unit of the University Hospital of Turin, were prospectively recruited and assessed for cardiometabolic risk by the Endocrinology Unit, by undergoing laboratory and instrumental tests. Results: The following prevalences were observed: arterial hypertension (52%), type 2 diabetes mellitus (7%), dyslipidemia (56%), osteoporosis (42%), and vertebral fracture (30%). At the univariate analysis, the enrolled pts were divided according to serodiagnosis, GC therapy and disease remission. No statistically significant results were highlighted stratifying population by serodiagnosis. Pts with high disease activity showed lower bone mineral density (BMD) values [BMD femoral trochanter: 0.53± 0.08 vs 0.60 ± 0.08 (g/m2), p=0.031] and T-score value on bone densitometry [T-score Femoral total:-1.88 ± 0.53 vs-1.07 ± 0.83, p=0.005], higher percentage of osteoporosis [67% vs 27%, p=0.047] and vertebral fractures [60% vs 12%, p=0.001], and higher sarcopenia score [SARC-F: 5 (3-7) vs 2 (2-4), p=0.020], in comparison with pts with remission disease. These differences were not confirmed when the population was divided according to the use of GC therapy. For CV risk factors, disease activity group showed a trend of higher prevalence compared to remission group, but without reaching statistical significance. At the multivariate analysis, advanced age (p=0
Se sei accreditato in BVS-P effettua l'accesso per utilizzare i nostri servizi.
DOI : 10.1136/annrheumdis-2023-eular.1767
Keywords
autoantibody; copeptin; endogenous compound; glucocorticoid; adult; bone densitometry; bone density; cardiometabolic risk; cardiovascular risk; cardiovascular risk factor; chronic inflammation; comorbidity; conference abstract; controlled study; drug therapy; dyslipidemia; endocrinology; exercise; female; gender; human; hypertension; major clinical study; male; morbidity; mortality; non insulin dependent diabetes mellitus; osteoporosis; preliminary data; prevalence; prospective study; remission; rheumatoid arthritis; rheumatology; risk assessment; SARC-F questionnaire; sarcopenia; serodiagnosis; spine fracture; statistical significance; steroid therapy; trabecular bone; univariate analysis; university hospital;